Biotech News

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss "New Aspects in Substance Use Treatment" at The Annual International Society of Addiction Medicine Conference

Adial Pharmaceuticals (ADIL)Adial Pharmaceuticals2023-10-31 08:30 ESTConference / presentation

CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Chief Medical Officer of...

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Stock data

Close: 6.22 USD
Market cap: 5.06M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss "New Aspects in Substance Use Treatment" at The Annual International Society of Addiction Medicine Conference

Related news

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals

Recent company news

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data